Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819253) titled 'Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy' on Sept. 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).

Primary Sponsor: Aswan University

Condition: Proliferative Diabetic Retinopathy (PDR)

Intervention: Drug: Ranibizumab 0.5 mg

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: July 1, 2023

Target Sample Size: 80

Countries of Recruitment: Egypt

To know more, visit https://clinicaltrials.gov/study/NCT0...